Home
|
About IAC
|
Contact
|
A-Z Index
|
Donate
|
Shop
|
SUBSCRIBE
Immunization Action Coalition

World Health Organization

WHO Position Papers: GACVS meetings

View all Pandemic influenza Travel
GACVS meetings Quality control
Needle safety Special reports
 

Position Papers - GACVS Meetings

GACVS: 29th Meeting, December 11–12, 2013
Safety profile of Japanese encephalitis (JE) chimeric vaccine; safety of inactivated poliovirus vaccines (IPV); increased occurrence of febrile seizures with a seasonal influenza vaccine; update on intussusception following rotavirus vaccine administration; human papillomavirus vaccines safety (HPV); and vaccine safety monitoring manual.
PDF
GACVS: 28th Meeting, June 12–13, 2013
Pentavalent vaccine in Asian countries; zoster vaccine safety and varicella vaccine safety in immunocompromised populations; immunization during pregnancy; yellow fever vaccine safety during mass immunization campaigns in sub-Saharan Africa; safety profile of Japanese encephalitis vaccines; update on human papillomavirus vaccines; and update on pandemic influenza vaccine (Pandemrix) and narcolepsy.
PDF
GACVS: 27th Meeting, December 5–6, 2012
Varicella vaccines; pandemic influenza vaccines; live attenuated dengue vaccines; and Global Vaccine Safety Initiative.
PDF
GACVS: 26th Meeting, June 6–7, 2012
The safety of thimerosal; the safety of aluminum adjuvants; the safety profile of influenza vaccines during pregnancy; and also reviewed 3 general issues for vaccine pharmacovigilance: safety of immunization during pregnancy and lactation; causality assessment for serious individual cases of adverse events following immunization (AEFI); and core variables for AEFI monitoring.
PDF
GACVS: 25th Meeting, December 7–8, 2011
The safety of influenza A(H1N1)pdm09 vaccines; rotavirus vaccines and intussusception; vaccine safety in pregnancy and lactation; global network for post-marketing surveillance and AEFI monitoring; and implementing the Global Vaccine Safety Blueprint
PDF
GACVS: 24th Meeting, June, 2011
The committee reviewed new data on the safety profile of meningococcal A conjugate vaccine, a new approach for assessing the causes of serious adverse events following immunization (AEFI), preparation of information sheets describing the safety profile of important vaccines, and the development of global strategies to enhance capacity to monitor and respond to vaccine safety issues in low-income and middle-income countries.
7/22/11
PDF
Rotavirus Vaccine and Intussusception: Report from an expert consultation
July, 22 2011
PDF
Statement on Narcolepsy and Vaccination
April 21, 2011
HTML
GACVS: 23rd Meeting, December 8-9, 2010
Rotavirus vaccine and intussusception; Safety of pandemic influenza A(H1N1) 2009 vaccines; Yellow fever vaccine and HIV infection; Meningitis A conjugate vaccine.
PDF
GACVS: 22nd Meeting, June 16-17, 2010
The committee reviewed the safety of pandemic A (H1N1) influenza vaccines, an apparent increase in febrile reactions following administration of a seasonal influenza vaccine in Australia, the finding of DNA from porcine circoviruses in rotavirus vaccines, the safety of live attenuated hepatitis A vaccines, the safety profile of a prequalified meningococcal A conjugate vaccine, and new data on yellow fever vaccine-related risks.
PDF
GACVS: 21st Meeting, December 3-4, 2009
The committee reviewed the safety of pandemic A (H1N1) influenza vaccines and the safety profile of a meningococcus A conjugate vaccine that will soon be deployed in sub-Saharan Africa. The committee also discussed the use of BCG vaccine in areas with a high prevalence of infection with HIV and reviewed progress with global monitoring of adverse events following immunization.
PDF
GACVS: 20th Meeting, June 17-18, 2009
The Committee reviewed the safety profile of a malaria vaccine entering phase III clinical development, updated the safety profiles of rotavirus and human paillomavirus (HPV) vaccines, discussed preparedness for novel influenza virus vaccines and completed a review of the safety of measles vaccines in persons infected with HIV.
PDF
GACVS: 19th Meeting, December 17-18, 2008
Issues discussed included: Safety profiles of rotavirus vaccines and human papillomavirus (HPV) vaccines, discussed several vaccine safety alerts in immunization programs supported by WHO, and reviewed the progress of its support programs.
PDF
GACVS Response: October 2008
Global Advisory Committee on Vaccine Safety: response to the paper (in press) by Y. Mikaeloff and colleagues in Neurology entitled "Hepatitis B vaccine and the risk of CNS inflammatory demyelination in childhood"
HTML
GACVS: 18th Meeting, June 18-19, 2008
Issues discussed included: yellow fever vaccines; more studies and enhanced surveillance to better understand the relative risks and benefits of vaccination against yellow fever; and the alleged association between vaccination and progression of inherited mitochondrial diseases.
HTML  |  PDF
GACVS: 17th Meeting, December 12-13, 2007
Issues discussed included: Guillain-Barré Syndrome and vaccination; and hepatitis B vaccination and rheumatoid arthritis.
HTML  |  PDF
GACVS: 16th Meeting, June 12-13, 2007
Issues discussed included: statements on Menactra update, monitoring vaccine safety, safety of BCG, and safety of rotavirus vaccine.
HTML  |  PDF
GACVS: 15th Meeting, November 29-30, 2006
Issues discussed included: Monitoring vaccine safety; report of the WHO Expert Committee on Biological Standardization; safety of vaccine formulations; vaccinating adolescents and young adults: problems with coincidental pathologies and safety assessments; safety of mumps vaccine strains; safety of BCG vaccine in HIV-infected children; update on Menactra and Guillain-Barré syndrome; pandemic influenza vaccines; safety of Japanese encephalitis vaccination in India; safety of pneumococcal conjugate vaccine.
PDF
GACVS: 14th Meeting, June 6-7, 2006
Issues discussed included: Vaccine safety monitoring and the WHO Programme for International Drug Monitoring; post-marketing surveillance of rotavirus vaccines; safety of squalene; Immunogenic overload; safety of pandemic influenza vaccines; safety issues of varicella vaccines; modus operandi of the Committee and additional information.
PDF
GACVS: 13th Meeting, December 1-2, 2005
Issues discussed included: Statements on pandemic influenza vaccine, adjuvants, rotavirus vaccine, subacute sclerosing panencephalitis and measles vaccine, chronic fatigue syndrome and hepatitis B vaccine, conjugate meningococcal vaccine and Guillain-Barré Syndrome, and an update on the Vaccine Safety Net project.
PDF
GACVS: 12th Meeting, June 9-10, 2005
Issues discussed included: Statements on mouse brain-derived Japanese encephalitis vaccine, safety of SA 14-14-2 Japanese encephalitis vaccine, isoniazid resistance of bacilli Calmette-Guerin strains, international drug monitoring, thimerosal, safety of hexavalent vaccines, subacute sclerosing panencephalitis and measles vaccination, and national regulatory authorities planning workshops.
PDF
GACVS: 11th Meeting, December 2-3, 2004
Issues discussed included: Statements on the safety of adjuvants, thimerosal, residual cellular DNA in vaccines, transmissible spongiform encephalopathies, potential risk of vaccines produced in yeast, safety of hexavalent vaccines, and yellow fever vaccine.
PDF
GACVS: 10th Meeting, June 10-11, 2004
Issues discussed included: Statements on the safety of adjuvants, dengue vaccine safety, and effect of DTP vaccination on child survival.
PDF
GACVS: 9th Meeting, December 3-4, 2003
Issues discussed included: Statements on intranasal influenza virus vaccine, influenza vaccines and neurological complications, influenza vaccination of women during pregnancy, safety issues in the poliomyelitis eradication campaign, and more.
PDF
GACVS: 8th Meeting, June 11-12, 2003
Issues discussed included: Adverse events following mumps vaccination; safety of smallpox vaccines; safety of BCG vaccination in immunocompromised individuals; thimerosal.
PDF
GACVS: 7th Meeting, December 16-17, 2002
Issues discussed included: MMR and autism; oculorespiratory syndrome; hepatitis B vaccination and leukaemia.
PDF
GACVS: 6th Meeting, June 20-21, 2002
Issues discussed included: Safety of thimerosal-containing vaccines; Hepatitis B vaccine and leukaemia; hepatitis B vaccine and multiple sclerosis; aluminum-containing vaccines and macrophagic myofasciitis; Bell palsy following intranasal vaccination; potential adverse impact of routine vaccination on child survival.
PDF
GACVS:5th Meeting, March 23, 2001
Issues discussed included: Causality assessment of adverse events following immunization.
PDF
GACVS: 1st Meeting, September 14-15, 1999
Issues discussed included: About GAVCS; macrophagic myofasciitis and aluminum-containing vaccines.
PDF
This page was reviewed on February 28, 2014
Immunization Action Coalition  •  Saint Paul, MN
tel 651-647-9009  •  fax 651-647-9131
 
This website is supported in part by a cooperative agreement from the National Center for Immunization and Respiratory Diseases (Grant No. 5U38IP000290) at the Centers for Disease Control and Prevention (CDC) in Atlanta, GA. The website content is the sole responsibility of IAC and does not necessarily represent the official views of CDC.